keyword
MENU ▼
Read by QxMD icon Read
search

Schizoaffective disorder

keyword
https://www.readbyqxmd.com/read/28932600/abnormal-n400-semantic-priming-effect-may-reflect-psychopathological-processes-in-schizophrenia-a-twin-study
#1
Anuradha Sharma, Heinrich Sauer, Holger Hill, Claudia Kaufmann, Stephan Bender, Matthias Weisbrod
OBJECTIVE: Activation of semantic networks is indexed by the N400 effect. We used a twin study design to investigate whether N400 effect abnormalities reflect genetic/trait liability or are related to psychopathological processes in schizophrenia. METHODS: We employed robust linear regression to compare N400 and behavioral priming effects across 36 monozygotic twin pairs (6 pairs concordant for schizophrenia/schizoaffective disorder, 11 discordant pairs, and 19 healthy control pairs) performing a lexical decision task...
2017: Schizophrenia Research and Treatment
https://www.readbyqxmd.com/read/28926346/coprophagic-asphyxiation-in-an-intellectually-disabled-woman
#2
Stephanie LeeAnne Erickson, Aaron David Gambrell, James Fulcher, Michael Ward
The ingestion of one's own feces is referred to as coprophagia. In this report, the author discusses a case of coprophagia-associated death in a 36-year-old woman. The woman had a history of intellectual disability, bipolar disorder, and schizoaffective disorder and was living in a group home. At autopsy, examination of the upper airway revealed 4 distinct spherical boli of impacted fecal matter in the oral cavity and pharynx. Death was attributed to asphyxia due to aspiration of stool bolus during an episode of coprophagia...
September 19, 2017: American Journal of Forensic Medicine and Pathology
https://www.readbyqxmd.com/read/28923068/using-blood-cytokine-measures-to-define-high-inflammatory-biotype-of-schizophrenia-and-schizoaffective-disorder
#3
Danny Boerrigter, Thomas W Weickert, Rhoshel Lenroot, Maryanne O'Donnell, Cherrie Galletly, Dennis Liu, Martin Burgess, Roxanne Cadiz, Isabella Jacomb, Vibeke S Catts, Stu G Fillman, Cynthia Shannon Weickert
BACKGROUND: Increases in pro-inflammatory cytokines are found in the brain and blood of people with schizophrenia. However, increased cytokines are not evident in all people with schizophrenia, but are found in a subset. The cytokine changes that best define this subset, termed the "elevated inflammatory biotype", are still being identified. METHODS: Using quantitative RT-PCR, we measured five cytokine mRNAs (IL-1β, IL-2 IL-6, IL-8 and IL-18) from peripheral blood of healthy controls and of people with schizophrenia or schizoaffective disorder (n = 165)...
September 18, 2017: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/28918417/-clinical-features-of-psychotic-and-non-psychotic-bipolar-patients
#4
Zsuzsanna Belteczki, Zoltan Rihmer, Julia Ujvari
BACKGROUND: Psychotic symptoms are common in the case of manic, depressive and mixed episodes of bipolar disorder; however, the assessment of delusions and hallucinations is frequently improper, thus the patients presenting also psychotic symptoms are treated based on their diagnosis of schizophrenia, schizoaffective disorder or paranoia. Psychotic symptoms in bipolar disorder result less favourable outcomes and course of illness. METHODS: 365 patients (106 males, 259 females) were hospitalized in or institution from January 1st 2015 to September 30th 2016, who were diagnosed with bipolar disorder according to the ICD-10 criteria...
June 2017: Neuropsychopharmacologia Hungarica
https://www.readbyqxmd.com/read/28902459/exome-sequences-of-multiplex-multigenerational-families-reveal-schizophrenia-risk-loci-with-potential-implications-for-neurocognitive-performance
#5
Mark Z Kos, Melanie A Carless, Juan Peralta, Joanne E Curran, Ellen E Quillen, Marcio Almeida, August Blackburn, Lucy Blondell, David R Roalf, Michael F Pogue-Geile, Ruben C Gur, Harald H H Göring, Vishwajit L Nimgaonkar, Raquel E Gur, Laura Almasy
Schizophrenia is a serious mental illness, involving disruptions in thought and behavior, with a worldwide prevalence of about one percent. Although highly heritable, much of the genetic liability of schizophrenia is yet to be explained. We searched for susceptibility loci in multiplex, multigenerational families affected by schizophrenia, targeting protein-altering variation with in silico predicted functional effects. Exome sequencing was performed on 136 samples from eight European-American families, including 23 individuals diagnosed with schizophrenia or schizoaffective disorder...
September 13, 2017: American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics
https://www.readbyqxmd.com/read/28899614/measuring-pathology-using-the-panss-across-diagnoses-inconsistency-of-the-positive-symptom-domain-across-schizophrenia-schizoaffective-and-bipolar-disorder
#6
Ariana E Anderson, Maxwell Mansolf, Steven P Reise, Adam Savitz, Giacomo Salvadore, Qingqin Li, Robert M Bilder
Although the Positive and Negative Syndrome Scale (PANSS) was developed for use in schizophrenia (SZ), antipsychotic drug trials use the PANSS to measure symptom change also for bipolar (BP) and schizoaffective (SA) disorder, extending beyond its original indications. If the dimensions measured by the PANSS are different across diagnoses, then the same score change for the same drug condition may have different meanings depending on which group is being studied. Here, we evaluated whether the factor structure in the PANSS was consistent across schizophrenia (n = 3647), bipolar disorder (n = 858), and schizoaffective disorder (n = 592)...
August 16, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28895941/outcome-reporting-bias-in-randomized-controlled-trials-investigating-antipsychotic-drugs
#7
M Lancee, C M C Lemmens, R S Kahn, C H Vinkers, J J Luykx
Recent literature hints that outcomes of clinical trials in medicine are selectively reported. If applicable to psychotic disorders, such bias would jeopardize the reliability of randomized clinical trials (RCTs) investigating antipsychotics and thus their extrapolation to clinical practice. We therefore comprehensively examined outcome reporting bias in RCTs of antipsychotic drugs by a systematic review of prespecified outcomes on ClinicalTrials.gov records of RCTs investigating antipsychotic drugs in schizophrenia and schizoaffective disorder between 1 January 2006 and 31 December 2013...
September 12, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28893329/epidemiology-of-psychotic-depression-systematic-review-and-meta-analysis
#8
E Jääskeläinen, T Juola, H Korpela, H Lehtiniemi, M Nietola, J Korkeila, J Miettunen
Large amount of data have been published on non-psychotic depression (NPD), schizophrenia (SZ), and bipolar disorder, while psychotic depression (PD) as an own entity has received much smaller attention. We performed a systematic review and meta-analyses on epidemiology, especially incidence and prevalence, risk factors, and outcomes of PD. A systematic search to identify potentially relevant studies was conducted using four electronic databases and a manual search. The search identified 1764 unique potentially relevant articles, the final study included 99 articles...
September 12, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28888918/effects-of-psychopharmacological-treatment-with-antipsychotic-drugs-on-the-vascular-system
#9
REVIEW
Kai G Kahl, Mechthild Westhoff-Bleck, Tillmann H C Krüger
Psychopharmacological treatment with antipsychotic drugs is an essential part of guideline-based treatment strategies in psychotic disorders, such as schizophrenia, schizoaffective disorders, and delusional disorders. Other mental disorders frequently treated with antipsychotic drugs are bipolar disorders, and major depressive disorder. Furthermore, antipsychotic drugs are often given in emergency and surgical units for the treatment of metabolic or postoperative delirium. Antipsychotic drugs can exert direct and indirect effects on the vascular system, potentially leading to severe complications such as thromboembolism...
September 6, 2017: Vascular Pharmacology
https://www.readbyqxmd.com/read/28882686/effects-of-peer-social-interaction-on-performance-during-computerized-cognitive-remediation-therapy-in-patients-with-early-course-schizophrenia-a-pilot-study
#10
Luis R Sandoval, Betzamel López González, William S Stone, Synthia Guimond, Cristina Torres Rivas, David Sheynberg, Susan S Kuo, Shaun Eack, Matcheri S Keshavan
BACKGROUND: Recent studies show that computer-based training enhances cognition in schizophrenia; furthermore, socialization has also been found to improve cognitive functions. It is generally believed that non-social cognitive remediation using computer exercises would be a pre-requisite for therapeutic benefits from social cognitive training. However, it is also possible that social interaction by itself enhances non-social cognitive functions; this possibility has scarcely been explored in schizophrenia patients...
September 4, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28880494/clinical-psychopathology-in-youth-at-familial-high-risk-for-psychosis
#11
Jai L Shah, Neeraj Tandon, Debra M Montrose, Diana Mermon, Shaun M Eack, Jean Miewald, Matcheri S Keshavan
AIM: While the course of psychopathology has been explored from an index mental health diagnosis onwards, there are few detailed, prospective studies of the occurrence of clinical psychopathology in youth with familial risk for severe mental illnesses such as psychosis. We sought to describe the appearance of Axis I psychopathology in a unique sample of adolescents with a family history of schizophrenia (FHR). METHODS: One hundred and sixty two first- and second-degree relatives (mean age 15...
September 7, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28866716/blood-serum-concentrations-of-kynurenic-acid-in-patients-diagnosed-with-recurrent-depressive-disorder-depression-in-bipolar-disorder-and-schizoaffective-disorder-treated-with-electroconvulsive-therapy
#12
Marcin Olajossy, Bartosz Olajossy, Sebastian Wnuk, Emilia Potembska, Ewa Urbańska
OBJECTIVES: The aim of the present study was to compare blood serum kynurenic acid (KYNA) concentrations measured before ECT and after 1, 6 and 12 electroconvulsive treatment (ECT) sessions in patients with diagnoses of recurrent depressive disorder (RDD), depression in bipolar disorder (DBD) and schizoaffective disorder (SAD). METHODS: The study group comprised of 50 patients with ICD-10 diagnoses of RDD, DBD and SAD. Blood serum KYNA concentrations were determined and clinical assessment was performed using the MADRS and the GAF scale...
June 18, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/28865717/measuring-learning-potential-in-people-with-schizophrenia-a-comparison-of-two-tasks
#13
Melisa V Rempfer, Joan M McDowd, Catana E Brown
Learning potential measures utilize dynamic assessment methods to capture performance changes following training on a cognitive task. Learning potential has been explored in schizophrenia research as a predictor of functional outcome and there have been calls for psychometric development in this area. Because the majority of learning potential studies have utilized the Wisconsin Card Sorting Test (WCST), we extended this work using a novel measure, the Rey Osterrieth Complex Figure Test (ROCFT). This study had the following aims: 1) to examine relationships among different learning potential indices for two dynamic assessment tasks, 2) to examine the association between WCST and ROCFT learning potential measures, and 3) to address concurrent validity with a performance-based measure of functioning (Test of Grocery Shopping Skills; TOGSS)...
August 24, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28861176/prevalence-of-obesity-and-diabetes-in-patients-with-schizophrenia
#14
Aniyizhai Annamalai, Urska Kosir, Cenk Tek
AIM: To compare the prevalence of diabetes in patients with schizophrenia treated at a community mental health center with controls in the same metropolitan area and to examine the effect of antipsychotic exposure on diabetes prevalence in schizophrenia patients. METHODS: The study was a comprehensive chart review of psychiatric notes of patients with schizophrenia and schizoaffective disorder treated at a psychosis program in a community mental health center. Data collected included psychiatric diagnoses, diabetes mellitus diagnosis, medications, allergies, primary care status, height, weight, body mass index (BMI), substance use and mental status exam...
August 15, 2017: World Journal of Diabetes
https://www.readbyqxmd.com/read/28857758/greater-metacognition-and-lower-fear-of-negative-evaluation-potential-factors-contributing-to-improved-stigma-resistance-among-individuals-diagnosed-with-schizophrenia
#15
Ruth L Firmin, Lauren Luther, Michelle P Salyers, Kelly D Buck, Paul H Lysaker
BACKGROUND: Stigma resistance, one's ability to block the internalization of stigma, appears to be a key domain of recovery. However, the conditions in which one is most likely to resist stigma have not been identified, and models of stigma resistance have yet to incorporate one's ability to consider the mind of others. The present study investigated the impact of the interaction between metacognition, or one's ability to form an integrated representation of oneself, others, and the world, and fear of negative evaluation on one's ability to resist stigma...
2017: Israel Journal of Psychiatry and related Sciences
https://www.readbyqxmd.com/read/28851345/ethical-acceptability-of-offering-financial-incentives-for-taking-antipsychotic-depot-medication-patients-and-clinicians-perspectives-after-a-12-month-randomized-controlled-trial
#16
Ernst L Noordraven, Maartje H N Schermer, Peter Blanken, Cornelis L Mulder, André I Wierdsma
BACKGROUND: A randomized controlled trial 'Money for Medication'(M4M) was conducted in which patients were offered financial incentives for taking antipsychotic depot medication. This study assessed the attitudes and ethical considerations of patients and clinicians who participated in this trial. METHODS: Three mental healthcare institutions in secondary psychiatric care in the Netherlands participated in this study. Patients (n = 169), 18-65 years, diagnosed with schizophrenia, schizoaffective disorder or another psychotic disorder who had been prescribed antipsychotic depot medication, were randomly assigned to receive 12 months of either treatment as usual plus a financial reward for each depot of medication received (intervention group) or treatment as usual alone (control group)...
August 29, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28846054/severe-clinical-events-in-100-patients-with-schizophrenia-a-retrospective-clinical-description-using-a-system-specific-psychopathological-approach
#17
Moritz E Wigand, Fabian U Lang, Lea Reichhardt, Thomas G Schulze, Sebastian Walther, Thomas Becker, Markus Jäger
Catatonic states and numerous other severe clinical events can complicate the course of schizophrenia. Whether these severe courses are associated with particular system-specific symptom dimensions remain unclear. Aim is to assess the frequency of severe clinical events in a clinical population and to investigate the association of these events with sociodemographic data and system-specific psychopathology, combining qualitative and quantitative data. We performed a comprehensive retrospective description of a well-described and geographically stable sample of 100 patients with schizophrenia or schizoaffective disorder and linked severe clinical events with sociodemographic data at inclusion into the study (as indicators of social functioning) and symptoms at first admission, classified with the Bern Psychopathology Scale (BPS)...
August 28, 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/28844295/concentrations-in-plasma-clozapine-levels-in-schizophrenic-and-schizoaffective-patients
#18
Celso Iglesias García, Ana Iglesias Alonso, Julio Bobes
INTRODUCTION: There is great variability in plasma levels of clozapine. The objective of this study is to know the characteristics of patients treated with clozapine and the relationship between them and the variability of plasma levels. MATERIAL AND METHODS: Descriptive, cross-sectional study of all patients currently treated with clozapine in a Psychiatric Service with a diagnosis of schizophrenic psychosis or schizoaffective disorder. The present study assessed physical situation, psychopathology and functionality of the patients and explored the associations and correlations between clinical variables and plasma levels...
August 22, 2017: Revista de Psiquiatrí́a y Salud Mental
https://www.readbyqxmd.com/read/28839342/efficacy-of-valbenazine-nbi-98854-in-treating-subjects-with-tardive-dyskinesia-and-schizophrenia-or-schizoaffective-disorder
#19
John M Kane, Christoph U Correll, Grace S Liang, Joshua Burke, Christopher F O'Brien
BACKGROUND: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ on TD in subjects with schizophrenia/schizoaffective disorder (SCHZ) or mood disorder (mood disorder presented separately) who received up to 48 weeks of treatment. METHODS: KINECT 3 included: 6-week, double-blind, placebo (PBO)-controlled (DBPC) period (205 completers); 42-week VBZ extension (VE) period (124 completers): 4-week washout period (121 completers)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28839341/long-term-safety-and-tolerability-of-valbenazine-nbi-98854-in-subjects-with-tardive-dyskinesia-and-a-diagnosis-of-schizophrenia-or-mood-disorder
#20
Richard C Josiassen, John M Kane, Grace S Liang, Joshua Burke, Christopher F O'Brien
BACKGROUND: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with longer treatment duration (up to 48 weeks) were conducted to evaluate the long-term safety of this novel drug in subjects with TD. METHODS: The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT (NCT01688037: 6-week DBPC, 6-week open-label); KINECT 3 (NCT02274558: 6-week DBPC, 42-week blinded extension, 4-week drug-free follow-up); KINECT 4 (NCT02405091: 48-week open-label, 4-week drug-free follow-up)...
August 1, 2017: Psychopharmacology Bulletin
keyword
keyword
3236
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"